InMed Pharmaceuticals Inc. (INM) has a negative trailing P/E of 0.0, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -357,116.10%.
Criteria proven by this page:
Overall SharesGrow Score: 47/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -3.3 | 0.06 | 7.40 | 0.00 | - |
| 2017 | -9.3 | -0.36 | 5.24 | 0.00 | - |
| 2018 | -16.1 | -0.59 | 5.22 | 0.00 | - |
| 2019 | -5.7 | -0.25 | 4.14 | 0.00 | - |
| 2020 | -4.9 | 0.60 | 7.44 | 0.00 | - |
| 2021 | -1.7 | 0.09 | 2.34 | 0.00 | - |
| 2022 | 0.0 | 0.00 | 0.02 | 0.24 | - |
| 2023 | -0.3 | 0.00 | 0.14 | 0.55 | - |
| 2024 | -0.2 | 0.00 | 0.15 | 0.42 | - |
| 2025 | -0.4 | 0.01 | 0.17 | 0.64 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-32.58 | $0.00 | $-1.84M | - |
| 2017 | $-41.26 | $0.00 | $-3.44M | - |
| 2018 | $-49.35 | $0.00 | $-6.71M | - |
| 2019 | $-64.01 | $0.00 | $-10.01M | - |
| 2020 | $-58.11 | $0.00 | $-8.94M | - |
| 2021 | $-47.06 | $0.00 | $-10.2M | - |
| 2022 | $-42.70 | $1.09M | $-18.6M | -1707.3% |
| 2023 | $-4.31 | $4.14M | $-7.95M | -192.2% |
| 2024 | $-1.01 | $4.6M | $-7.68M | -166.9% |
| 2025 | $-11.44 | $4.94M | $-8.16M | -165.1% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $0.00 | $0.00 – $0.00 | $71M | $71M – $71M | 0 |
